A Study of Venetoclax and Dexamethasone Compared With Pomalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Inclusion Criteria:

- Documented diagnosis of multiple myeloma (MM) based on standard IMWG criteria.

- Measurable disease at screening as defined per protocol.

- Has received at least 2 prior lines of therapy as described in the protocol.

- Has had documented disease progression on or within 60 days after completion of the
last therapy.

- Has received at least 2 consecutive cycles of lenalidomide and be refractory to
lenalidomide, as defined per protocol.

- Has received at least 2 consecutive cycles of a proteasome inhibitor (PI).

- Has MM positive for t(11;14).

- An Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to
2.

- Laboratory values (liver, kidney and hematology laboratory values) that meet criteria
as described per protocol.

Exclusion Criteria:

- History of treatment with venetoclax or another B-Cell Lymphoma (BCL)-2 inhibitor or
pomalidomide.

- History of other active malignancies, including myelodysplastic syndromes (MDS),
within the past 3 years (exceptions described in the protocol).

- Evidence of ongoing graft-versus-host disease (GvHD) if prior stem cell transplant
(SCT).

- Prior treatment with any of the following: allogeneic or syngeneic SCT within 16 weeks
prior to randomization; or autologous SCT within 12 weeks prior to randomization.

- Known meningeal involvement of MM.

- Concurrent conditions as listed in the protocol.